DHURI CLINICAL LAB is a leading anatomic pathology and hematopathology laboratory focused on quality, innovation, and client services.

Reading more than 150,000 cases a year, our pathologists have a broad range of experiences and abilities to approach diagnostic challenges. We consider it of paramount importance to deliver excellent customer service. With that in mind, our medical staff is available throughout the business day for consultation.

Employing state-of-the-art diagnostic technologies, DHURI CLINICAL LAB is dedicated to comprehensive, high-quality, rapid-response cancer testing and the integration of these technologies into patient care. We provide valuable information that is critical for the diagnosis, prognosis, treatment, and monitoring of cancer. This leads to confident treatment decisions by oncologists and a more efficient way to determine and employ drug therapies that make improved patient care possible.

DHURI CLINICAL LAB offers several connectivity solutions for client convenience and efficiency, including PATHways™ for Web-based access to results and AP Gateway™ for direct laboratory information system (LIS) interface. In addition, our suite of Virtual Lab products provides Web-based access to flow cytometry data, as well as immunohistochemistry (IHC) and other slide images for convenient, timely access to results.

DHURI CLINICAL LAB also provides consultative services and second opinions to assist physicians and hospitals. For these clients, DHURI CLINICAL LAB can provide the necessary technical components or ancillary anatomic pathology testing to complement flow cytometry, IHC, fluorescent in situ hybridization (FISH), and/or molecular studies performed in their laboratories.

IHC Primary Antibody Menu to accompany the IHC test request form.

PATHways custom reporting solutions for pathologists.

CEBPA, c-KIT, and NPM1 mutation analysis for risk prognosis in acute myelogenous leukemia (AML).

MPL Mutation Analysis for primary myelofibrosis and essential thrombocythemia.

PIK3CA Mutation Analysis. Mutations in PIK3CA may indicate prognosis and drug response in liver, colorectal, and breast cancer.

KRAS and BRAF mutation status has been shown to provide prognostic and potentially predictive information for patients considered for anti-EGFR monoclonal antibody therapies.

PNH Evaluation by flow cytometry: High-sensitivity flow from DHURI CLINICAL LAB allows for detection of smaller PNH clones than standard flow cytometry.